Overview

* Puma Q2 2025 product revenue rises to $49.2 mln, driven by NERLYNX demand

* Adjusted EPS for Q2 beats analyst expectations, per LSEG data

* Co reports net income of $5.9 mln for Q2, reversing prior year loss

Outlook

* Puma expects Q3 net product revenue between $46 mln and $48 mln

* Company forecasts full-year total revenue of $212-$222 mln

* Puma anticipates Q3 net income between $2 mln and $4 mln

* Company sees full-year net income of $23-$28 mln

Result Drivers

* NERLYNX SALES - Increased demand for NERLYNX drove product revenue to $49.2 mln in Q2 2025

* EXPENSE REDUCTION - Lower SG&A expenses due to decreased legal fees contributed to profitability

* ALISERTIB DEVELOPMENT - Increased R&D expenses linked to alisertib study activity

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $49.20

Product mln

Revenue

Q2 Beat $0.15 $0.1 (3

Adjusted Analysts

EPS )

Q2 EPS $0.12

Q2 Beat $7.50 $4.20

Adjusted mln mln (2

Net Analysts

Income )

Q2 Net $5.90

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Puma Biotechnology Inc ( PBYI ) is $4.00, about 18.8% above its August 6 closing price of $3.25

* The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)